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Despite promising preclinical results, average response rates to anti-VEGF therapies, such as
bevacizumab, are reduced for most cancers, while incurring in remarkable costs and side
effects. Currently, there are no biomarkers available to select patients that can benefit from
this therapy. Depending on the individual tumor, anti-VEGF therapies can either block or
promote metastasis. In this context, an assay able to predict individual responses prior to
treatment, including the impact on metastasis would prove of great value to guide treatment
options. Here we show that zebrafish xenografts are able to reveal different responses to
bevacizumab in just 4 days, evaluating not only individual tumor responses but also the
impact on angiogenesis and micrometastasis. Importantly, we perform proof-of-concept
experiments where clinical responses in patients were compared with their matching zeb-
rafish Patient-Derived Xenografts - zAvatars, opening the possibility of using the zebrafish
model to screen bevacizumab therapy in a personalized manner.
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Angiogenesis is a well-recognized hallmark of cancer, cri-tically involved in tumor growth and metastatic spread1.One of the key players in tumor-induced angiogenesis is
VEGF-A, which is often found upregulated in many solid tumors.
To target VEGF signaling several therapies were developed with
the hope of reverting tumor angiogenesis and therefore tumor
growth, referred as antiangiogenic therapies.
Bevacizumab is a humanized monoclonal antibody, whose
mechanism of action is to target and neutralize three human
VEGF-A isoforms2,3. The bound form prevents VEGF-A inter-
action with its receptors and, consequently, impairs signaling and
angiogenesis2,3. Currently, bevacizumab is used in the clinic as a
single agent or combined with antineoplastic drugs for several
advanced cancers. These include metastatic colorectal cancer
(CRC), metastatic breast cancer, non-small cell lung cancer,
ovarian cancer, metastatic renal carcinomas and glioblastomas3.
Food and Drug Administration approval of bevacizumab for
metastatic breast cancer was withdrawn after several studies and a
meta-analysis that showed a very limited efficacy in an unselected
breast cancer population4. European Medicines Agency, on the
other hand, kept its approval. The lack of predictive biomarkers
of response/resistance does not allow a correct selection of
patients, leading the international breast cancer guidelines to
consider bevacizumab only in highly selected cases5.
Overall average response rates for bevacizumab as mono-
therapy are neither satisfactory nor consistent, ranging from
5.9% (metastatic melanoma) to 9.3% (metastatic breast cancer),
but can reach 54.8% in glioblastoma6–8. In addition, bevacizumab
treatment can be associated with serious side effects, such as
cardiovascular complications, bleeding and renal toxicity4,9,10.
Although VEGF-A signaling is mostly associated to angio-
genesis, tumor cells can also express receptors that respond to this
pathway, controlling tumor cell proliferation, survival and
migration11. It has been shown that VEGF-A may act on different
steps of the invasion-metastatic cascade12–15. Paradoxically,
depending on the tumor cells, VEGF-A inhibition can either
reduce or induce metastasis. This effect was observed not only in
preclinical mouse models but also in patient responses to ther-
apy11–29.
Tumor-specific heterogeneous and contradicting responses can
relate to the pleiotropic effects of VEGF-A and may explain the
poor average overall response rates of bevacizumab and other
antiangiogenic therapies. Therefore, identification of patients who
benefit from these therapies will increase efficacy rates and avoid
unnecessary toxicities and healthcare costs. Unfortunately, no
clinical biomarker has been identified to date and the promising
in vitro tests currently under development, such as organoids, are
unable to evaluate the impact on metastasis. Thus, an in vivo
model that directly challenges tumor cells to therapy is urgently
needed. Currently, mouse Patient-Derived Xenografts (PDX) are
the established model and the adult zebrafish xenografts are
emerging30. However, mouse PDX take months to implant and to
evaluate therapy options and therefore are not feasible within the
time frame required for a clinical decision.
Recently, we developed zebrafish xenografts to screen ther-
apeutic options in advanced CRC31. Also, we and others have
shown that zebrafish xenografts can be used to screen for cancer-
driven angiogenesis and metastatic potential31–36. This is only
possible because the majority of cancer-associated human genes
are conserved in zebrafish, both in structure and function. The
same applies for the signaling pathways that control cell
proliferation, migration, death and differentiation32,35.
Moreover, vascular growth factors and the respective receptors, as
well as the signaling pathways that regulate mammalian vascular
development, are also well conserved between humans and
zebrafish37. Such conservation enables the study of different
cancer hallmarks, namely on tumor-induced angiogenesis and
metastasis.
With the aim of challenging zebrafish xenografts as an in vivo
screening platform for bevacizumab responses, we used several
representative tumor cell models of triple negative breast cancer
(TNBC) and CRC that express VEGF-A. In just 4 days, we were
able to evaluate the reported heterogeneity of responses to bev-
acizumab treatment on angiogenesis and metastasis, along with
its direct impact on tumor biology. As a proof-of-principle, we
also generated breast cancer and CRC zebrafish PDX (zPDX or
zAvatars) and show that we can detect similar phenotypic pro-
files. Importantly, we provide two case studies where the zAvatars
showed resistance to bevacizumab and their corresponding
patients progressed under treatment, corroborating our results.
Overall, our results suggest that zAvatars constitute a promising
in vivo model to decide bevacizumab treatment in a personalized
manner.
Results
Different tumoral features displayed in zebrafish xenografts.
We started by selecting several cancer cell lines known to express
VEGF-A (Supplementary Table 1) and characterized the corre-
sponding xenografts according to several hallmarks of cancer,
including cell proliferation, cell death, metastatic and angiogenic
potentials. For breast cancer, we selected Hs578T and MDA-MB-
468, both considered TNBC representative cell lines38. Whereas
Hs578T was derived from a primary breast carcinoma, MDA-
MB-468 was isolated from a pleural effusion metastasis originated
from a primary breast adenocarcinoma. For CRC, we selected
HCT116, SW620 and HT29 as representative cell lines. HCT116
was isolated from a primary colorectal carcinoma, HT29 from a
primary colorectal adenocarcinoma and SW620 was derived from
a lymph node metastasis, whose primary tumor was localized in
colon39. On Supplementary Table 1, we summarize the expres-
sion profile for the relevant cancer-driven mutations, expression
of ligands and receptors of VEGF family, as well as sensitivity to
bevacizumab, according to the available literature. All tumor cell
lines were injected into the perivitelline space (PVS) of 2 days
post fertilization (dpf) zebrafish larvae and analyzed at 4 days
post injection (dpi) for the several cancer hallmarks (Fig. 1a–e).
TNBC and CRC cell lines revealed different basal levels of
apoptosis, with representative TNBC cells showing higher level of
activated Caspase3 than CRC cells (Fig. 1f–j, u). In contrast,
quantification of proliferation shows that CRC representative
tumors present higher proliferative rates (Fig. 1f’–j’, v). A balance
between diverse cellular events, such as cell proliferation and cell
death, can contribute to different tumor sizes as observed at the
end of the 4 days assay (Fig. 1f–j, w). Hs578T TNBC xenografts
were the smallest tumors (AVG ~281 cells), correlating with their
higher basal apoptotic index and low proliferation. In contrast,
HCT116 CRC xenografts were the largest tumors (AVG ~2420
cells), which exhibited the highest proliferation rate and lowest
apoptotic index (Fig. 1u–w).
Given our goal of testing the antiangiogenic and metastatic
impact of bevacizumab treatment in zebrafish xenografts, we
analyzed tumor-induced angiogenesis by generating xenografts in
Tg(fli1:eGFP) transgenic zebrafish hosts, which have the vascu-
lature labeled with eGFP40. Most tumors showed a well-
vascularized network at their base (Fig. 1k–o, x). However,
Hs578T and HT29 had the additional capacity to recruit a dense
vessel network that infiltrates into the tumors, being Hs578T
tumors the most vascularized ones (vessel density ~32.4%)
(Fig. 1x). In order to assess the metastatic potential of each tumor,
we quantified the capacity of tumor cells to colonize the caudal
hematopoietic tissue (CHT) located in the tail region, the most
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distant site from injection. Interestingly, Hs578T TNBC xeno-
grafts that had the most vascularized tumors presented the lowest
capacity to colonize the CHT region (only ~3.6% of xenografts
presented micrometastasis in the CHT, N= 6/163, Fig. 1x, y). In
contrast, the MDA-MB-468 TNBC that recruits blood
vessels only to the base of the tumor, showed the highest
metastatic potential (~42.5%, N= 37/87, Fig. 1y). Nevertheless,
HT29 CRC that presented high vessel density (~14.9%, N= 28)
also showed a high metastatic potential (~36.7%, N= 98,
Fig. 1x, y). Our results thus show that there is no direct
correlation between vessel density and metastatic potential.
Consistently, previous studies performed in pancreatic and CRC
tumor models were also unable to show a correlation between
angiogenesis and metastasis41,42.
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Differential tumor response to bevacizumab treatment. To test
the effects of bevacizumab, we first tested several concentrations
of bevacizumab in the Embryonic medium (E3) (larvae swim-
ming medium), based on maximum plasma concentration
(Cmax) found in patients (90–140 μg/mL)43, which did not
induce any mortality (Supplementary Fig. 1a, see details in
“Methods”). We chose ~2 times the Cmax (250 μg/mL) as our
working concentration, since above this concentration would not
be feasible due to lack of antibody availability for animal
experiments. To further test the absorption of the bevacizumab
antibody, we conjugated the commercial bevacizumab to FITC.
Hs578T cell line was used to validate the protocol, since expresses
high levels of VEGF-A (Supplementary Table 1) and Hs578T
tumors were the most vascularized (Fig. 1k, x). At 3 dpi, when
tumors are established and vasculature developed, Hs578T
xenografts were incubated with bevacizumab-FITC for 24 h in the
E3 and imaged by confocal microscopy (Supplementary
Fig. 1b–f’). As depicted in Supplementary Fig. 1c–f’,
bevacizumab-FITC is detected specifically in the tumor region
and not in the tail of the same fish, demonstrating absorption and
specific binding to the human tumor cells.
Although bevacizumab is absorbed, we observed that to have a
clear phenotype (Fig. 2), not only tumor cells had to be
resuspended in bevacizumab (100 ng/mL)44 prior to injection
but also xenografts had to be incubated with bevacizumab in the
E3 for 3 consecutive days (250 μg/mL).
After protocol optimization, TNBC and CRC zebrafish
xenografts were generated and treated with bevacizumab
(Fig. 2a–e’, f, g, h). At 4 dpi, we were unable to detect significant
reduction of proliferation in any of the represented tumors
(Fig. 2f, quantification of mitotic figures or phosphohistone H3,
Supplementary Fig. 2a–a”, b, c).
However, analysis of cell death revealed a significant induction
of apoptosis in Hs578T TNBC xenografts (~1.6 fold, ****P <
0.0001) accompanied by a reduction in tumor size (~40% tumor
reduction, ****P < 0.0001) (Fig. 2g, h). Although we did not
observe an induction of apoptosis in other tumors, bevacizumab
induced a significant reduction of tumor size in both HCT116
(~22% tumor reduction, ****P < 0.0001) and SW620 (~25%
tumor reduction, ****P < 0.0001 ) CRC xenografts (Fig. 2g, h).
These results may point to an earlier onset of Caspase3 induction
or induction of alternative pathways of cell death. Even though
MDA-MB-468 and HT29 cells express ligands and receptors for
the VEGF family (Supplementary Table 1), both behaved as
resistant to bevacizumab and none of the parameters analyzed
were altered upon treatment (Fig. 2f–h ). These results are
consistent with previous studies performed in mouse
xenografts45,46.
Bevacizumab modulates angiogenesis and vessel normal-
ization. Next, we evaluated the impact of bevacizumab on the
tumor microenvironment, in particular on the angiogenic
potential of each tumor model (Fig. 3a–g, compare with Sup-
plementary Fig. 3—non-injected larvae).
Hs578T TNBC tumors that exhibited the highest angiogenic
potential were also the most affected by bevacizumab treatment,
reducing significantly both vessel density (~20% reduction,
**P= 0.0023) and vessel infiltration (~32% reduction, **P=
0.0027, Fig. 3a–a’, f, g, see representative Z stack for vessel
infiltration—Supplementary Movies 1 and 2 and Supplementary
Fig. 4a–a’ for serial slices). Along with Hs578T, HT29 CRC
tumors also showed a high angiogenic potential. However,
bevacizumab treatment neither affected the overall vessel density
or infiltration in HT29 tumors (Fig. 3e–e’, f, g, see representative
Z stack for vessel infiltration—Supplementary Movies 3, 4 and
Supplementary Fig. 4b–b’ for serial slices). These results are
consistent with previous studies performed in HT29 mouse
xenografts where anti-VEGF treatment had no antiangiogenic
effect45. In the remaining tumor models, MDA-MB-468, HCT116
and SW620 with simple vascularized periphery, we did not
observe a significant impact on vessel network (Fig. 3b–d’, f),
suggesting that vessels recruited to the base of these tumors are
dependent on other pro-angiogenic factors. Moreover, our results
also showed that the most vascularized tumors were also smaller
in size, suggesting that, in this short assay, angiogenesis is not a
consequence of tumor hypoxia but, rather, a read-out of the
balance of the available pro- and anti-angiogenic factors released
by tumor cells and, therefore, a useful reporter for angiogenic
potential (Supplementary Fig. 5).
Since bevacizumab is administered in the clinic intravenously,
we next investigated the impact of injecting bevacizumab in
circulation (100 ng/mL) in the most sensitive xenograft Hs578T.
We designed two settings: (i) injecting daily since 1 hpi during
4 days (Supplementary Fig. 6a) and (ii) injecting later when
tumor vessels are already formed (3 dpi), also during 4 days
(Supplementary Fig. 6h). In both settings, bevacizumab is able to
induce its antitumor effect. In setting a, bevacizumab induced a
significant increase of apoptosis (*P= 0.01) without tumor
size reduction, accompanied by a reduction of vessel infiltration
(*P= 0.016) (Supplementary Fig. 6b–g). In setting h, we
performed a time course, monitoring daily each xenograft. At
the end of the assay we observed a clearance of ~30% of tumors in
bevacizumab-treated xenografts but no clearance in the controls.
Also, bevacizumab-treated xenografts seem to present a higher
incidence of tumor size reduction, but we could not detect
reduction of angiogenesis (Supplementary Fig. 6i–o). Our original
protocol (cells preincubated with bevacizumab+ bevacizumab in
E3) provides a more robust effect. This may be due to the dosage
(in the E3 we apply a much higher concentration), but also
because of the timings. In our original protocol, cells have
bevacizumab exerting its activity as soon as cells are prepared.
Thus, if the assay is extended one more day or if we increase the
dosage and maintain the timings, we would probably observe the
tumor size reduction phenotype. In the second setting, the assay
Fig. 1 Characterization of zebrafish TNBC and CRC xenografts models. Human cancer cell lines (Hs578T, MDA-MB-468, HCT116, SW620 or HT29)
were fluorescently labeled with DiI (red) and injected into the perivitelline space (PVS) of 2 days post fertilization (dpf) Tg(fli1:eGFP) zebrafish larvae (a–e).
At 4 days post injection (dpi), zebrafish xenografts were evaluated regarding: apoptotic index—% of activated Caspase3 (f–j, u), mitotic index—% mitotic
figures (f’–j’, v), tumor size (f–j, w), angiogenic capacity (k–o, x) and metastatic potential (p–t, y). White arrowheads indicate mitotic figures. Apoptotic
index (u, ****P < 0.0001), mitotic figures (v, Hs578T versus MDA-MB-468 ****P < 0.0001, ***P= 0.0002, **P= 0.0049), tumor size (w, ****P < 0.0001,
**P= 0.0065, *P= 0.0129), total vessel density (x, ****P < 0.0001, **P= 0. 0045) and metastatic potential (y, ****P < 0.0001, HCT116 versus SW620
**P= 0.0036, SW620 versus HT29 **P= 0.0048, Fisher’s exact test) are expressed as AVG ± SEM. The number of xenografts analyzed are indicated in
the representative images and each dot represents one zebrafish xenograft. Results are from 3 (Hs578T and MDA-MB-468) and 2 (HCT116, SW620 and
HT29) independent experiments, which are highlighted in different colors corresponding to each individual experiment. Statistical analysis was performed
using an unpaired t-test or Fisher’s exact test. Statistical results: (ns) > 0.05, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001. Scale bars represent
50 μm. All images are anterior to the left, posterior to right, dorsal up and ventral down.
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terminates later in development (9 dpf) raising the possibility of
some interplay with the immune system that can lead to tumor
clearance. In summary, although intravenously experiments
mirror an ideal experimental design, they are time-consuming
and demanding to implement. Also, many xenografts die during
procedure, making it very difficult to obtain high numbers,
compromising the robustness of the assay. Therefore, we would
argue that our initial protocol is a good compromise of
practicality and feasibility.
Thus, we returned to our original protocol to further
characterize the tumor-related vessels in the most sensitive and
angiogenic tumors. To this end, a filament analysis was
performed, revealing that bevacizumab leads to a reduction of
the number of branching points, but has no impact on overall
vessel length in Hs578T tumors (Fig. 3h–j’, k, l).
It has been shown that, in general, tumor-related vessels are
heterogenous and tortuous and poorly perfused, consequently not
fully functional47. However, antiangiogenic therapies, by rebalan-
cing the pro- and anti-angiogenic factors, may revert this
phenotype leading to a vascular normalization47. Therefore, to
investigate vessel functionality and the impact of bevacizumab on
vessel normalization, we injected Hs578T cancer cells into Tg(fli1:
eGFP; Tg(gata1:DsRed)48, in which erythrocytes are labeled with
DsRed and the vascular system with eGFP (Fig. 3). In this way, we
could evaluate if the tumor-related blood vessels were functional,
i.e., able to transport red blood cells. Hs578T untreated xenografts
showed vascularized tumors, but we could not find any
erythrocytes inside these very abnormal and tortuous vessels. In
contrast, upon bevacizumab treatment, we could observe a clear
increase in the number of tumors with red blood cells inside the
vessels, suggesting that bevacizumab may normalize vessel
function (Fig. 3m–n’, o, P= 0.073).
Altogether, our data suggest that bevacizumab can modulate
not only vessel recruitment, but also vessel functionality.
Bevacizumab can enhance or impair micrometastatic potential.
VEGF-A is a pleiotropic molecule that can also impact on dif-
ferent steps of the invasion-metastatic cascade12–15. Previous
studies report that antiangiogenic therapies may have contra-
dictory effects, in some cases reduce metastatic disease while in
others promote it11–29. Therefore, we tested whether we could
detect these variable responses in our assay. We first evaluated the
impact of bevacizumab on the capacity of tumor cells to dis-
seminate and colonize distant sites, in particular, the CHT region.
At 4 dpi, the presence of micrometastasis in the CHT region was
quantified (Fig. 4a). Control Hs578T TNBC tumors had a
reduced capacity to form micrometastasis in the CHT region, as
previously observed (Fig. 1y). However, upon bevacizumab
treatment, we observed a 3.5-fold increase in the frequency of
micrometastasis in the CHT (from ~3.6% to ~12.8%, **P=
0.0041, Fig. 4b). In clear contrast, in MDA-MB-468 TNBC
tumors that exhibited the highest metastatic potential, bev-
acizumab treatment reduced the frequency of micrometastasis to
half (from ~42.5% to ~19.7%, **P= 0.0017, Fig. 4b). For CRC
tumors, bevacizumab increased the incidence of CHT metastasis
Fig. 2 Zebrafish xenografts reveal different tumor responses to bevacizumab. Human cancer cell lines (Hs578T, MDA-MB-468, HCT116, SW620 or
HT29) were injected into the PVS of 2 dpf Tg(fli1:eGFP) zebrafish larvae. Zebrafish xenografts were treated in vivo with bevacizumab and compared with
untreated controls. At 4 dpi, zebrafish xenografts were imaged by confocal microscopy (a–e’). The percentage of mitotic figures (f), apoptosis (g, ****P <
0.0001) and tumor size (h, ****P < 0.0001) were quantified. The outcomes are expressed as AVG ± SEM. The number of xenografts analyzed are indicated
in the representative images and each dot represents one zebrafish xenograft. Results are from 3 (Hs578T and MDA-MB-468) and 2 (HCT116, SW620
and HT29) independent experiments, which are highlighted in different colors corresponding to each individual experiment. Statistical analysis was
performed using an unpaired t-test. Statistical results: (ns) > 0.05, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001. Scale bars represent 50 μm. All
images are anterior to the left, posterior to right, dorsal up and ventral down.
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in SW620 xenografts (from ~22% to ~31%, *P= 0.0112, Fig. 4b)
but the impact of treatment on HCT116 and HT29 CRC xeno-
grafts was not significantly altered (P= 0.88 and P= 0.88,
respectively, Fig. 4b).
To further confirm these results, we investigated the presence
of micrometastasis in other organs beyond the CHT, namely the
brain, eye and gills and quantified the incidence of micrometas-
tasis in these multiple organs (Supplementary Fig. 7a–e).
Strikingly, our results show that bevacizumab was able to
significantly reduce the incidence of micrometastasis in multiple
sites per animal in MDA-MB-468 (from ~43.7 to ~23.4%, **P=
0.0081), HCT116 (from ~19 to ~2.6%, *P= 0.03) and HT29
(from ~44 to ~20%, **P= 0.0061) (Fig. 4c—presence of
micrometastasis in two or more sites). In contrast, in Hs578T
and SW620 xenografts that showed an increase in the CHT
incidence, we also did not observe an increase of metastasis in
other sites. These results highlight the complexity of the
metastatic process in response to bevacizumab, revealing that
bevacizumab can either promote or decrease the capacity of
tumor cells to disseminate and colonize distant sites. In addition,
bevacizumab may also influence organ preference, independent of
the origin of the tumors (colon or breast) (see Supplementary
Fig. 7a–e).
Bevacizumab impacts on different steps of the metastatic cas-
cade. Metastasis encompasses a multistep cascade of events that
could be divided into two stages49,50. The first steps involve
tumor cell detachment from the primary tumor by disruption
of cell–cell junctions and extracellular matrix degradation,
migration plus invasion of adjacent tissues and intravasation
into the bloodstream. The later steps comprise tumor cell
survival in circulation, extravasation from the blood or lym-
phatic vessels, and colonization at secondary sites49,50. To
better understand the effect of bevacizumab on the invasion-
metastasis cascade, we used our previously designed assay31 to
Fig. 3 Bevacizumab reduces angiogenesis and promotes vessel normalization. Human cancer cell lines (Hs578T, MDA-MB-468, HCT116, SW620 or
HT29) were fluorescently labeled with DiI (in red) and injected into the PVS of 2 dpf Tg(fli1:eGFP) zebrafish larvae. Zebrafish xenografts were treated
in vivo with bevacizumab and compared with untreated controls. At 4 dpi, zebrafish xenografts vasculature was imaged by confocal microscopy (max Z-
projections) (a–e’). Total vessel density (f, **P= 0.0023) and vessel infiltration (g, **P= 0.0027) were quantified. Filament analysis was performed in
Hs578T tumor-related vasculature. Hs578T xenografts confocal images of untreated and Bevacizumab-treated (h, h’) were used to perform 3D projections
using Imaris (i–i’) and skeletonized images on ImageJ (j–j’). Number of branching points (k, **P= 0.007) and average vessel length (l, P= 0.61) were
quantified by filament analysis. To analyze the functionality of Hs578T tumor-related vessels, tumor cells were labeled with DeepRed (in gray) to generate
xenografts in Tg(fli1:eGFP; gata1:DsRed) zebrafish larvae. Xenografts were treated in vivo with bevacizumab and compared with untreated controls. At 4 dpi,
zebrafish xenografts were mounted in low melting agarose to be visualized by live-imaging confocal microscopy (m–n’). The percentage of xenografts with
erythrocytes inside blood vessels was quantified (o). All outcomes are expressed as AVG ± SEM. The number of xenografts analyzed are indicated in the
representative images and each dot represents one zebrafish xenograft. Results are from 2 independent experiments, which are highlighted in different
colors corresponding to each individual experiment. Statistical analysis was performed using an unpaired t-test or Fisher’s exact test. Statistical results:
(ns) > 0.05, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001. Scale bars represent 50 μm. All images are anterior to the left, posterior to right, dorsal up
and ventral down.
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distinguish between these early and late events and address the
potential/proficiency of the different tumor cells to perform
these steps (Fig. 5a). MDA-MB-468 and SW620 tumors, which
displayed opposite phenotypes to bevacizumab regarding
metastatic potential, were injected either in the PVS alone (i.e.,
without cells in circulation—no circ) or directly into circulation
(circ) and PVS, thus bypassing the first metastatic steps. At
4 dpi, we quantified frequency of xenografts with the presence
of micrometastasis in the CHT (Fig. 5b). Strikingly, our data
suggest that bevacizumab can impact both in early and late
stages of the invasion-metastasis cascade. Upon bevacizumab
treatment, we observed a ~60% reduction of the capacity of
MDA-MB-468 TNBC tumors to go through the early steps
(from ~19.27% to ~7.8%, *P= 0.02, Fisher’s exact test, Fig. 5b).
In contrast, when cells were directly injected into circulation,
bevacizumab treatment showed a tendency to double the inci-
dence of SW620 CRC micrometastasis (from ~19% to ~44%,
P= 0.06, Fisher’s exact test, Fig. 5b). This result suggests that
bevacizumab might increase the capacity of SW620 cells to
perform the later steps of metastasis formation.
Altogether, our results reveal the possible multiple
functions of VEGF-A signaling in the metastatic cascade in a
Fig. 4 Bevacizumab can both promote and impair the metastatic potential of human cancers. Representative image of an MDA-MB-468 zebrafish
xenograft with a tumor in the PVS and several micrometastasis spread throughout the zebrafish larvae body, namely in brain, eye, gills and CHT (a).
Human cancer cell lines (Hs578T, MDA-MB-468, HCT116, SW620 or HT29) were injected into the PVS of 2 dpf Tg(fli1:eGFP) zebrafish larvae. Zebrafish
xenografts were treated in vivo with bevacizumab and compared with untreated controls. At 4 dpi, zebrafish xenografts were imaged by a fluorescent
stereoscope to detect tumor cells throughout the zebrafish body (b). The percentage of xenografts that display micrometastasis in the CHT region
was quantified (b, Hs578T **P= 0.0042, MDA-MB-468 **P= 0.0017, SW620 *P= 0.0112) and the outcomes are expressed as AVG ± SEM. Results
are from 5 (Hs578T and SW620), 3 (MDA-MB-468) and 2 (HCT116 and HT29) independent experiments. The presence of micrometastasis in other
organs besides the CHT was also quantified, namely in the brain, eye and gills, in untreated and bevacizumab-treated xenografts and the incidence of
micrometastasis in two or more metastatic sites was determined (c, MDA-MB-468 from ~43.7 to ~23.4%, **P= 0.0081; HCT116 from ~19 to ~2.6%,
*P= 0.0308; and HT29 from ~44 to ~20%, **P= 0.0061). Statistical analysis was performed using a Fisher’s exact test. Statistical results: (ns) > 0.05,
*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001.
Fig. 5 Bevacizumab can modulate early and late metastatic steps. Schematic representation to distinguish between early and late metastatic steps (a).
Injected xenografts were sorted into two groups—xenografts with only cells in the PVS and xenografts with cells in circulation. MDA-MB-468 and SW620
micrometastasis in the CHT region were quantified from both groups (b, MDA-MB-468 *P= 0.0246 and SW620 P= 0.06). Results are from
2 independent experiments and outcomes are expressed as AVG ± SEM. The number of xenografts analyzed are indicated below the graphs. Statistical
analysis was performed using a Fisher’s exact test. Statistical results: (ns) > 0.05, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001.
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tumor-dependent fashion: in some cases promoting early
metastatic events, whereas in others the later steps.
Differential response to bevacizumab in zAvatars. Next, as a
proof-of-concept, we tested whether we could observe these
paradoxical effects of bevacizumab in zAvatars. We processed
three breast cancer and three CRC surgical resected samples
(Supplementary Table 2) and treated the resulting zAvatars
with bevacizumab. For all we analyzed angiogenesis, induction
of cell death by apoptosis, tumor mass and incidence of
micrometastasis. In contrast to other surgical resected sam-
ples31, we could not detect any significant recruitment of blood
vessels to the tumor mass in these particular zAvatars and,
therefore we did not proceed to quantify angiogenesis (Sup-
plementary Fig. 8a–f’).
Nevertheless, we could observe a variety of phenotypes, some
reminiscent of the paradoxical effects observed in the tumor cell
lines models, but also new profiles (Fig. 6a–c). Due to the reduced
amount of sample, our zPDX numbers were low, reducing the
statistical power of analysis. In order to address this, we
performed an additional effect size analysis—Cohen’ D with a
Hedges’ g correction for low number of samples (xenografts, see
“Methods”). Nonetheless, we are aware that we cannot take major
conclusions, only profiles.
zPDX#1 presented a phenotype reminiscent of SW620, with
bevacizumab showing a tendency to shrink the tumor size
(Fig. 6b, ~50% reduction, P= 0.095, g= 1.11) but an increase in
micrometastasis incidence (Fig. 6c, from ~10% to ~45%, P=
0.087, g= 0.78, see Supplementary Fig. 8g–l). On the other hand,
zPDX#2 and zPDX#4 had a profile reminiscent to MDA-MB-468,
with bevacizumab having no antitumor effect (Fig. 6b, P= 1.0
and g= 0.03, P= 0.42 and g= 1.03, respectively), but a tendency
to reduce the micrometastasis incidence (Fig. 6c, zPDX#2 from
~42% to 0%, P= 0.072, g= 1.06; zPDX#4 from ~20% to 0%, P=
0.167, g= 0.64). zPDX#3 exhibited a profile similar to Hs578T
TNBC, where we could detect a significant increase in apoptosis
upon bevacizumab treatment (Fig. 6a, from ~6.5% to ~18.7%,
*P= 0.01, g= 1.75), accompanied by a tendency to shrink the
tumor (Fig. 6b, ~21% reduction, P= 0.42, g= 0.56) but increase
micrometastasis frequency (Fig. 6c, from ~12% to ~53%,
P= 0.26, g= 0.44).
In contrast, zPDX#5 and zPDX#6 showed a different profile. In
zPDX#5 we observed an increase in apoptosis (Fig. 6a, from
~22% to 42%, *P= 0.01, g= 1.51) and in zPDX#6 a shrinkage of
the tumor mass (Fig. 6b, ~44% reduction, *P= 0.03, g= 1.08),
both accompanied by a tendency to reduce micrometastasis
incidence (Fig. 6c, zPDX#5 from ~32% to ~11%, P= 0.08, g=
0.49; zPDX#6 from ~62% to 37%, P= 0.07, g= 0.50). In these last
“case studies,” bevacizumab not only would control the growth of
localized tumors but also possibly prevent the development of
occult micrometastasis at distant sites.
Comparison of patient’s response with their matching zAva-
tars. Next, in order to compare responses to bevacizumab
between the zebrafish model and the corresponding patient
clinical response, we searched in the Champalimaud Foundation
cryopreserved biobank for patients that during the course of their
disease might have been treated with bevacizumab. Within this
biobank, we were able to retrieve two patients who had available
sample material and could constitute two case studies to generate
zAvatars.
The first case is a 60-year-old male patient, herein Patient#7,
that was diagnosed with a colon adenocarcinoma in April 2017
with synchronous peritoneal carcinomatosis and treated with
CAPOX (full clinical history in Supplementary Fig. 9a, see
legend). The tumor progressed under CAPOX treatment and
was subsequently submitted to surgery (October 2017).
Pathology of the surgical specimen revealed a high-grade
mucinous adenocarcinoma. In late January 2018 postoperative
chemotherapy was proposed with CAPOX+ bevacizumab.
After three cycles, whole body computerized tomography scan
imaging revealed “de novo” parenchymal and subcapsular liver
lesions, as well as mesenteric nodules and abdominal wall
lesions not previously present (Fig. 7a–c’). Clinical and imaging
progression was assumed. After three subsequent lines of
treatment (FOLFIRI+ bevacizumab, TAS-102+ bevacizumab,
Regorafenib) to which the disease was refractory, the patient
died. We had access to a surgical specimen from Patient#7
before bevacizumab treatment. We processed this sample
(Supplementary Fig. 10a–a’ and Supplementary Table 3) and
generated the matching zPDX for bevacizumab testing. We
analyzed apoptosis and metastatic potential and observed no
significant antitumor effect in either parameter (Fig. 7d–e’, f, g,
induction of apoptosis P= 0.47, g= 0.29; metastatic potential
from ~10% to ~14%, P= 0.73 Fisher’s exact test, g= 0.11).
Thus, consistent with the patient refractory response the
corresponding zAvatars were not responsive to bevacizumab
treatment.
The second patient was a 64-year-old man with a long
clinical history, who underwent surgery for a left colon
adenocarcinoma in 2011 followed by several rounds of
treatment (full clinical history in Supplementary Fig. 9b, see
legend). The biopsy that we had access was retrieved after
bevacizumab treatment resistance (i.e., progression under
treatment and “de novo” lesions, Fig. 7h–j’). Although this
case does not constitute the ideal setting for our study, we
sought to investigate whether we could detect resistance in the
matching zAvatars. The biopsy was processed (Supplementary
Fig. 10b–b’ and Supplementary Table 3) and zPDX were
generated and treated with bevacizumab. Our results show that
bevacizumab had no significant impact on induction of
apoptosis in the tumor (Fig. 7m P= 0.18, g= 0.82). However,
and although it did not reach statistical significance, we could
detect an increment in the incidence of micrometastasis in the
CHT when treated with bevacizumab (Fig. 7n from ~8% to
~23%, ~2.8 times more micrometastasis, P= 0.11 Fisher’s exact
test, g= 0.42). These results suggest that resistance to
bevacizumab treatment in the zPDX may reflect the patients’
outcome. Overall, our results show the feasibility of the zPDX
assay to inquire the outcome of bevacizumab treatment in
patients.
Discussion
Anti-VEGF-A or antiangiogenic therapies have been under
intensive debate, especially due to the controversial effects of
these therapies on metastasis and disease progression. Although
these therapies can control established primary tumor and
metastasis in some patients, later, after treatment withdrawal or
even under treatment, some tumors progress51. This progression
may be manifested by regrowth of the established disease or the
appearance of additional metastatic lesions51. It has been sug-
gested that this progression may be the result of multiple
mechanisms of resistance/adaptation that occur after months of
treatment4,16. However, it is also under debate whether these
antiangiogenic therapies, which control established disease, could
simultaneously promote “de novo” invasive and micrometastatic
lesions51. In other words, these treatments may potentiate the
development of hidden micrometastasis at distant sites that will
only manifest after a considerable time delay. In contrast, there
are also many reports that suggest that antiangiogenic therapies
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can reduce metastatic potential15,27 and therefore constitute a
very important antimetastatic therapy. However, no biomarker to
identify which patients will benefit from these therapies has been
found to date.
Therefore, taking into account the diversity of mechanisms that
can be involved in the metastatic process, a functional assay that
“reads” the metastatic potential of each tumor in an in vivo
context, independent of the genetic makeup/mechanism, would
be fundamental to screen for these therapies with possible det-
rimental effects in a preclinical or clinical setting.
Here, we show that zebrafish cancer xenografts can reflect the
panoply of pro- and anti-metastatic effects of bevacizumab in a
time window of just 4 days. In the mice model, it has been shown
that antiangiogenic therapy can increase the incidence of
Fig. 6 zPDX reveal different response profiles to bevacizumab. Human breast cancer or CRC surgical resected samples were injected into the PVS of 2
dpf Tg(fli1:eGFP) zebrafish larvae. zPDXs were treated in vivo with bevacizumab and compared with untreated controls. At 4 dpi, zebrafish xenografts were
imaged by confocal microscopy. The percentage of apoptosis (a, zPDX#3 *P= 0.0159, g= 1.75 and zPDX#5 *P= 0.0101, g= 1.51) and tumor size (b, *P=
0.0381, g= 1.08) were quantified. In parallel, zebrafish xenografts were analyzed in a fluorescent stereoscope to detect micrometastasis in the CHT region,
followed by confocal confirmation (c). The outcomes are expressed as AVG ± SEM. The number of xenografts analyzed are indicated below the graphs.
Results are from 1 independent experiment. Statistical analysis was performed using an unpaired t-test for apoptosis and tumor size and a Fisher’s exact
test for micrometastasis. Statistical results: (ns) > 0.05, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001. Cohen’s D 1988 scale of effect size with
Hedges’ g correction (g): g= 0,2 low; g= 0.5 moderate; g= 0.8 high.
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metastasis in a time frame of just 1 week21,22. This quick impact
of 1 week in mice and 4 days in zebrafish suggest that late
metastatic progression in patients may not be a sole consequence
of a slow process of resistance/adaptation, but rather as a result of
a micrometastatic potential already present in the beginning of
therapy, which can be either enhanced or reduced by treatment.
The zebrafish model provides a reduction of scale to single cell
resolution, enabling us to detect single circulating cells and
micrometastasis composed of just a few cells. Therefore, this
reduction of size allows also a reduction of the time scale,
enabling us to evaluate the early effects of therapy on escaping/
circulating tumor cells, which in patients in early stages are
undetectable, but in the future might give rise to metastasis.
Finally, we show correlation of resistance in zAvatars with clinical
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resistance/progression under bevacizumab treatment in two case
studies.
Overall, our results suggest that zAvatars are a promising
model to screen bevacizumab treatment in a personalized manner
to avoid unwanted effects and healthcare costs. The zAvatar rapid
assay will not be able to predict the result of slow resistance/
adaptation mechanisms, but may predict which patients will have
more chance to have a positive/negative immediate response and
possibly predict the development of future micrometastasis.
Future work will be aimed at testing the predictive value of the
zAvatar model to forecast the effects of bevacizumab on disease
progression with many more patients.
Methods
Animal care and handling. In vivo experiments were performed in the zebrafish
model (Danio rerio), which was maintained and handled in accordance with
European Animal Welfare Legislation and Champalimaud Fish Platform Program.
The experiments of this project were performed at the Champalimaud Vivarium,
which is licensed by the National Authority for Animal Health (DGAV) and
complies with European Guidelines (2010/63/EU), National Laws (113/2013) and
FELASA guidelines and recommendations concerning laboratory animal welfare,
scientific use and proper education/training of all personnel performing animal
work. The study and procedures were approved by the Champalimaud Animal
Welfare & Ethical Review Body (ORBEA) and DGAV.
Zebrafish lines. Tg(fli1:eGFP)40 has a eGFP under the fli1 promoter expressed
specifically in endothelial cells, allowing the visualization of both blood and lym-
phatic vascular systems. Tg(gata1:DsRed)48 allows visualization of erythrocytes.
Transparent zebrafish line, casper52, was also used for Supplementary Fig. 1.
Human tissue. Human breast cancer and CRC resected samples used for zPDXs
establishment were obtained from Champalimaud Hospital and Hospital Professor
Doutor Fernando Fonseca, respectively, with written informed consents, approved
by both Hospital’s Ethics Committees. The study was approved by the Ethics
Committee of the Champalimaud Foundation and the Hospital Professor Fer-
nando Fonseca. All tumor samples were collected after signed informed consent.
Human cancer cell lines. Hs578T and MDA-MB-468 were kindly provided by
Mónica Bettencourt Dias’ Laboratory at Instituto Gulbenkian Ciência. SW620 and
HT29 were originally from American Type Culture Collection. HCT116 cells were
provided by Dr Ângela Relógio (Charité Medical University of Berlin). All cell lines
were authenticated through short tandem repeat profile analysis and tested for
mycoplasma.
Cell culture. Cancer cell lines were cultured and expanded to 70–80% confluence
in Dulbecco’s Modified Eagle Medium High Glucose (Biowest) supplemented
with 10% fetal bovine serum (Sigma-Aldrich) and 1% Penicillin-Streptomycin
10,000 U/mL (Hyclone). For Hs578T, culture medium was supplemented with
insulin at 10 μg/mL (Sigma-Aldrich).
Cell labeling. Cells were labeled with lipophilic dyes: vybrant CM-DiI (VybrantTM
CM-DiI Thermo Fisher Scientific) at a concentration of 2 μL/ml for TNBC cells or
4 μL/mL for CRC cell lines or Deep Red (CellTrackerTM-Thermo Fisher Scientific)
at a concentration of 1 μl/ml according to manufacturer’s instructions. TNBC cells
were resuspended to a final concentration of 0.50 × 106 cells/μL and CRC cells to
0.25 × 106 cells/μL.
Human tissue processing. The samples were collected in rich media containing a
mixture of antibiotics and antifungals and cryopreserved until injection, as pre-
viously described31. When defrosted, tumor tissues were minced in Mix1 (Sup-
plementary Table 3). Subsequently, CRC tissue was digested with Liberase (Roche)
and breast tissue with Collagenase (20 mg/mL, Worthington) plus Hyaluridase
(3 mg/mL, Sigma) at 37 °C. Tumor cell suspension was filtered and centrifuged at
1200 rpm for 4 min. For cell labeling, tumor cells were incubated with the fluor-
escent cell tracker DiI (10 μL/mL) in Mix2 (Supplementary Table 3) for 15 min at
37 °C and then for 5 min on ice. Tumor cells were checked for viability with trypan
blue dye exclusion. Cancer cells were resuspended in Mix1 with human EGF
(50 ng/mL, Peprotech) to a final concentration of ~0.25 × 106 cells/μL. A small
aliquot of the processed/dissociated tumor sample was stained with MGG
Grunwald-Giemsa (Bio-Optica) method according to the manufacturer’s
instructions.
Zebrafish xenografts injection. Cancer cells were microinjected into the PVS of
anesthetized 2 dpf zebrafish. In general, ~800 (bigger cells) to ~1500 (smaller
cells) cells are injected, depending on the size of the tumor cells. Zebrafish xeno-
grafts were kept at 34 °C until the end of the experiments. At 1 dpi, zebrafish
xenografts were screened regarding the presence or absence of a tumoral mass.
Xenografts with cells in the yolk sac, cell debris or non-injected zebrafish larvae
were discarded, whereas successful ones were grouped according to tumor size. All
xenografts were kept at 34 °C until the end of the experiment. At 4 dpi, xenografts
were sacrificed and fixed with 4% formaldehyde (Thermo Scientific) and kept in
100% methanol at −20 °C for long-term storage. We designed the test to span
4 days not only due to animal ethics constrains but more importantly to give time
to perform immunofluorescence, confocal imaging and analysis in a useful time
window for future patient advice.
Drug administration. We tested several concentrations of bevacizumab (see
Supplementary Fig. 1) and chose 250 μg/mL, ~2× the Cmax (maximum plasma
concentration found in patients43) as our working concentration. Besides the
addition of bevacizumab to the E3 medium at 1 dpi at 250 μg/mL, bevacizumab
was added at 100 ng/mL to the cell suspension prior to injection (concentration
used in vitro for cell lines44). For the intravenous injections, bevacizumab was
injected at 100 ng/mL into the pericardia space using fluorescent red dextran to
check entry into circulation.
Bevacizumab-FITC labeling. Bevacizumab was labeled with N-
hydroxysuccinimide-ester fluorescein (Thermo Fisher Scientific) according to
manufacturer’s instructions.
Whole-mount immunofluorescence. Antibodies used: anti-activated Caspase3
(rabbit, Cell Signaling-CST), anti-GFP (mouse, Roche), anti-human HLA-MHC
class I subunit (rabbit, AbCAM), and anti-phosphohistone H3 (rabbit, Merck
Millipore). Primary antibodies were used at 1:100 and secondary antibodies at
1:400. Nuclei were counterstained with DAPI at 50 μg1mg/mL.
Imaging and quantification. All images were obtained in a Zeiss LSM 710
confocal microscope, generally with 5 μm interval. Quantification analysis
was performed using ImageJ software. For tumor size, cell counter plugin
was used and the number of total DAPI (tumor size)=AVG (3 slices Zfirst,
Zmidle, Zlast) × total n° slices/1.5. Mitotic figures and activated Caspase3 were
quantified manually along the stack and divided by the tumor size of the
respective tumor.
Metastatic potential quantification. To distinguish between early and late
metastatic events, human TNBC and CRC cell lines were injected into the PVS only
(no circ) or into PVS plus circulation (circ). At 1 hpi, xenografts were sorted into
these two groups. At 4 dpi, the number of xenografts that had micrometastasis in
Fig. 7 zPDX bevacizumab treatment response may predict relapse and correlates with patients' outcome. Computerized tomography scans of Patient#7
(a–c’) and Patient#8 (h–j’) of different regions, including liver (a, a’, i, i’), lung (h, h’), mesenteric region (b, b’) and abdominal wall (c, c’, j, j’) in both pre-
and post-treatment settings. Red arrows highlight metastasis. Human patient surgical/biopsy samples were injected into the PVS of 2 dpf Tg(fli1:eGFP)
zebrafish larvae. zPDXs were treated in vivo with bevacizumab and compared with untreated controls. At 4 dpi, zebrafish xenografts were imaged by
confocal microscopy (d–e’, k–l’). Activated caspase3 was quantified in both groups (f, zPDX#7 P= 0.4682 and g= 0.29; m, zPDX#8 P= 0.1817 and g=
0.82). In parallel, the percentage of xenografts that display micrometastasis in the CHT region was quantified (g, zPDX#7 P = 0.73 and g = 0.11; n,
zPDX#8 P = 0.11 and g = 0.42). The outcomes are expressed as AVG ± SEM. Number of zPDX analyzed for each condition is indicated in the figure.
Results are from 1 independent experiment. Statistical analysis was performed using an unpaired t-test for apoptosis and a Fisher’s exact test for
micrometastasis. Statistical results: (ns) > 0.05, *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001. Cohen’s D 1988 scale of effect size with Hedges’ g
correction (g): g= 0,2 low; g= 0.5 moderate; g= 0.8 high. Scale bars represent 50 μm. All images are anterior to the left, posterior to right, dorsal up, and
ventral down.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-1015-0 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:299 | https://doi.org/10.1038/s42003-020-1015-0 | www.nature.com/commsbio 11
the CHT region was determined:
%Micrometastasis in CHT ¼ #Xenografts at 4 dpi with cell in the CHT
#Total of xenografts analyzed
´ 100:
Vessel density, vessel infiltration and vessel normalization analysis. Vessel
density was assessed throughout z projections of corresponding images using
ImageJ53 Z Projection tool and the percentage of eGFP fluorescent per tumor was
quantified. To analyze vessel infiltration, the superficial slices of the tumor were not
considered. For vessel normalization analysis, Hs578T TNBC cells were injected
into the PVS of 2dpf Tg(fli1:eGFP; gata1:DsRed). At 4 dpi, the percentage of
xenografts presenting erythrocytes inside tumor-related vasculature was deter-
mined in two steps: (1) divide the number of xenografts with erythrocytes inside
tumor-related vessels by the total number of xenografts analyzed and (2) multiply
by 100.
Vessel density ¼ eGFP area
Tumor area
; Vessel infiltration ¼ eGFP area
Core of the tumor
:
Vessel filament analysis. Vessels analysis was performed using FIJI/ImageJ. The
workflow was automated using a macro which follows a modified version of the
workflow delineated by ref. 54.
The analysis is performed on confocal 3D stacks of 1 μm. To minimize the
impact of the fish vessels on the analysis, the region of interest was manually
selected for each data set. The images were filtered and background subtracted
prior to segmentation using Fiji built-in function. To analyze the length and
branching properties of the vascular network we performed skeletonization of the
image mask using the “Skeletonize 2D/3D” built-in function, while for skeleton
analysis used the “Analyze Skeleton” function. Relevant parameters were extracted
and statistical analysis was performed.
Statistics and reproducibility. Statistical analysis was performed using the
GraphPad Prism software version 8. All data were challenged by Shapiro-Wilk and
D'Agostino & Pearson normality tests. A Gaussian distribution was only assumed
for datasets that pass both normality tests and were analyzed by an unpaired t-test
with Welch’s correction. Datasets without Gaussian distribution were analyzed by
unpaired and nonparametric Mann–Whitney test. For metastasis incidence and
vessel normalization analysis the Fisher’s exact test was used. For vessel infiltration
data, the unpaired and nonparametric Kolmogorov–Sminorv test was performed.
In addition, for small number of samples, namely the zPDXs analysis, we per-
formed an effect size analysis—Cohen’s D with a Hedges’ g correction (g). For all
the statistical analysis, P value (P) is from a two-tailed test with a confidence
interval of 95%. Statistical differences were considered significant whenever P <
0.05 and statistical output was represented by stars as follows: non-significant
(ns) > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. All the graphs
presented the results as average (AVG) ± standard error of the mean (SEM).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Authors can confirm that all relevant data are included in the article and/or
its Supplementary information files. Remaining data is available on request from the
corresponding author.
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